Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors

por Smith, Amanda M., Dun, Matthew D., Lee, Erwin M., Harrison, Celeste, Kahl, Richard, Flanagan, Hayley, Panicker, Nikita, Mashkani, Baratali, Don, Anthony S., Morris, Jonathan, Toop, Hamish, Lock, Richard B., Powell, Jason A., Thomas, Daniel, Guthridge, Mark A., Moore, Andrew, Ashman, Leonie K., Skelding, Kathryn A., Enjeti, Anoop, Verrills, Nicole M.
Publicado 2016

Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia

por Murray, Heather C., Enjeti, Anoop K., Kahl, Richard G. S., Flanagan, Hayley M., Sillar, Jonathan, Skerrett-Byrne, David A., Al Mazi, Juhura G., Au, Gough G., de Bock, Charles E., Evans, Kathryn, Smith, Nathan D., Anderson, Amanda, Nixon, Brett, Lock, Richard B., Larsen, Martin R., Verrills, Nicole M., Dun, Matthew D.
Publicado 2020

Shwachman–Bodian–Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia

por Dun, Matthew D., Mannan, Abdul, Rigby, Callum J., Butler, Stephen, Toop, Hamish D., Beck, Dominik, Connerty, Patrick, Sillar, Jonathan, Kahl, Richard G. S., Duchatel, Ryan J., Germon, Zacary, Faulkner, Sam, Chi, Mengna, Skerrett-Byrne, David, Murray, Heather C., Flanagan, Hayley, Almazi, Juhura G., Hondermarck, Hubert, Nixon, Brett, De Iuliis, Geoff, Chamberlain, Janis, Alvaro, Frank, de Bock, Charles E., Morris, Jonathan C., Enjeti, Anoop K., Verrills, Nicole M.
Publicado 2020